Journal: Cell stem cell
Article Title: A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development.
doi: 10.1016/j.stem.2018.03.012
Figure Lengend Snippet: Figure 4. Post-transcriptional Regulation of HMGA2 Isoforms (A) Left: Normalized luciferase (Renilla) activity in Dgcr8-KO MEF of constructs carrying 30 UTR sequences of HMGA2-L (Rluc-30UTRwt_HMGA2-L) or a mutant derivative depleted for miRNA sites (Rluc-30UTRmt_HMGA2-L). Right: Normalized luciferase (Renilla) activity in Dgcr8-KO MEF of constructs carrying 30 UTR sequences of HMGA2-L (Rluc-30UTRwt_HMGA2-L) or HMGA2-S (Rluc-30UTRwt_HMGA2-S). Normalized luciferase activities were reported with respect to Rluc-30UTRmt_HMGA2-L (left) or Rluc-30UTRwt_HMGA2-S (right), set to 100%. Mean ± SEM values are shown. Unpaired t test was used; *p < 0.05, **p < 0.01, ***p < 0.005, borderline (०= 0.055). (B) Quantification of miRNAs of interest in PC-3 and HPC-5F cells measured by qRT-PCR. U6 small nuclear RNA (snRNA) was used as control. (C) Relative quantification of HMGA2 isoforms in PC-3 and HPC-5F cells transduced with lentiviral constructs carrying the HMGA2 ORFs equipped with their corresponding 30 UTRs (HMGA2-L+30UTRwt and HMGA2-S+30UTRwt) or a derivative HMGA2-L isoform mutated at its miRNA sites (HMGA2-L+30UTRmt). Infected cells were treated with actinomycin D (Act-D) and harvested at the indicated time points. Expression values were normalized to HPRT1 control and then reported with respect to HMGA2-S+30UTRwt, set to 1. Mean ± SEM values are shown. ANOVA was used; *p < 0.05, **p < 0.01, ***p < 0.005.
Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD34 PE-Cy7 BD Biosciences Cat. 348791; CLONE 8G12 CD38 PE-Cy5 BD Biosciences Cat. 555461; CLONE HIT2 CD90 PE BD Biosciences Cat. 555596; CLONE 5E10 CD45RA FITC BioLegend Cat. 304105; CLONE HI100 DAPI solution BD Biosciences Cat. 564907 CD45RA V450 BD Biosciences Cat. 560362; CLONE HI100 CD133/1 APC Miltenyi Biotec Cat. 130-090-826; CLONE AC133 CD19 PE BD Biosciences Cat. 349209; CLONE 4G7 CD45 PE-Cy5 Coulter CLONE Immu19.2 CD33 APC BD Biosciences Cat. 340474; CLONE P67.6 CD45 APC-Cy7 BD Biosciences Cat. 561863; CLONE 2D1 V5 MBL Cat. M167-3 H3K4me2 Diagenode Cat. 035-050 Biological Samples Cord Blood CD34+ Cells Lonza Cat. 2C-101 Cord Blood CD34+ Cells AllCells Cat. CB008F Fetal Liver CD34+ Cells AllCells Cat. FL-CD34-002F Bone Marrow CD34+ Cells AllCells Cat. ABM017F Bone Marrow CD34+ Cells Lonza Cat. 2M-101C Chemicals, Peptides, and Recombinant Proteins Actinomycin D Sigma-Aldrich Cat. A1410 Doxycycline Hyclate Sigma-Aldrich Cat. D9891 Protamine Sulfate Sigma-Aldrich Cat. P4020 Recombinant Human SCF Peprotech Cat. 300-07 Recombinant Human FLT3L Peprotech Cat. 300-19 Recombinant Human TPO Peprotech Cat. 300-18 Recombinant Human IL6 Peprotech Cat. 200-06 Retronectin Clontech Cat. T100A DOTAP Liposomal Transfection Reagent Sigma-Aldrich Cat. 11202375001 DharmaFECT Duo Transfection Reagent Dharmacon Cat. T-2010-03 Critical Commercial Assays Dual-Luciferase Reporter Assay System Promega Cat. E1910 TruSeq RNA Library Prep Kit v2 Illumina Cat. RS-122-2001 SMART-Seq v4 Ultra Low Input RNA Kit Clontech Cat. 634888 Nextera XT DNA Library Preparation Kit Illumina Cat. FC-131-1024 nCounter Human v2 miRNA Expression Assay NanoString Technologies Cat. GXA-MIR2-24 ChiP-Seq Assay Broad Institute Epigenomics Program N/A Experimental Models: Cell Lines PC-3 ATCC Cat. CRL-1435 K562 ATCC Cat. CCL-243 HPC and HPC-5F Doulatov et al., 2013 N/A DGCR8 knockout MEF Novus Biologicals Cat. NBP2-25171 (Continued on next page) Cell Stem Cell 22, 575–588.e1–e7, April 5, 2018 e1
Techniques: Luciferase, Activity Assay, Construct, Mutagenesis, Quantitative RT-PCR, Control, Transduction, Infection, Expressing